Gemcitabine : A Review of Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma, an exocrine tumor, is the most common type of cancer of the pancreas and one of the top five most prominent causes of cancer-associated mortality worldwide. The survival rate for pancreatic cancer is sadly less than 8%. The high fatality rate is partly related to late diagnosis and partly to the aggressive nature of malignant cells that disseminate to nearby tissues at an early stage of the disease, making treatment difficult. Available treatment choices consist of both medical and surgical: removal of the tumor, use of various medications like chemotherapeutic drugs and immunotherapeutic agents, radiation therapy, and targeted drug therapy. Since most patients suffer from advanced cancer at the time of diagnosis, chemotherapy becomes the primary therapeutic option in such cases. Drugs like Gemcitabine, Abraxane, FOLFIRINOX, and newer combination therapies are all effective in management, either curatively or palliatively. However, chemoresistance poses a significant challenge. Several factors, both intrinsic and acquired, are involved in drug resistance. Here, we review the mechanism of action of the first-line chemotherapy drugs in pancreatic cancer and various factors associated with cancer chemoresistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Critical reviews in oncogenesis - 24(2019), 2 vom: 06., Seite 199-212 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sarvepalli, Deepika [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.07.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1615/CritRevOncog.2019031641 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302835962 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302835962 | ||
| 003 | DE-627 | ||
| 005 | 20231225111550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1615/CritRevOncog.2019031641 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1009.xml |
| 035 | |a (DE-627)NLM302835962 | ||
| 035 | |a (NLM)31679214 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sarvepalli, Deepika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gemcitabine |b A Review of Chemoresistance in Pancreatic Cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.07.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Pancreatic ductal adenocarcinoma, an exocrine tumor, is the most common type of cancer of the pancreas and one of the top five most prominent causes of cancer-associated mortality worldwide. The survival rate for pancreatic cancer is sadly less than 8%. The high fatality rate is partly related to late diagnosis and partly to the aggressive nature of malignant cells that disseminate to nearby tissues at an early stage of the disease, making treatment difficult. Available treatment choices consist of both medical and surgical: removal of the tumor, use of various medications like chemotherapeutic drugs and immunotherapeutic agents, radiation therapy, and targeted drug therapy. Since most patients suffer from advanced cancer at the time of diagnosis, chemotherapy becomes the primary therapeutic option in such cases. Drugs like Gemcitabine, Abraxane, FOLFIRINOX, and newer combination therapies are all effective in management, either curatively or palliatively. However, chemoresistance poses a significant challenge. Several factors, both intrinsic and acquired, are involved in drug resistance. Here, we review the mechanism of action of the first-line chemotherapy drugs in pancreatic cancer and various factors associated with cancer chemoresistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Albumin-Bound Paclitaxel |2 NLM | |
| 650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
| 650 | 7 | |a folfirinox |2 NLM | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 650 | 7 | |a Deoxycytidine |2 NLM | |
| 650 | 7 | |a 0W860991D6 |2 NLM | |
| 650 | 7 | |a Irinotecan |2 NLM | |
| 650 | 7 | |a 7673326042 |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 700 | 1 | |a Rashid, Mamoon Ur |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Asad Ur |e verfasserin |4 aut | |
| 700 | 1 | |a Ullah, Waqas |e verfasserin |4 aut | |
| 700 | 1 | |a Hussain, Ishtiaq |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Badar |e verfasserin |4 aut | |
| 700 | 1 | |a Jehanzeb, Sundas |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Abdul Kareem |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Akriti Gupta |e verfasserin |4 aut | |
| 700 | 1 | |a Khetpal, Neelam |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Sarfraz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncogenesis |d 1995 |g 24(2019), 2 vom: 06., Seite 199-212 |w (DE-627)NLM012938904 |x 0893-9675 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2019 |g number:2 |g day:06 |g pages:199-212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1615/CritRevOncog.2019031641 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2019 |e 2 |b 06 |h 199-212 | ||